Talk:Olaparib

This is the talk page for discussing improvements to the Olaparib article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Olaparib.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Question

Does it inhibit just PARP1 or other PARP enzymes ? Rod57 (talk) 11:43, 22 October 2009 (UTC)[reply]

Exaggerated coverage

The Journal of the National Cancer Institute gave olaparib as an example of exaggerated coverage in the news media. Promoting Healthy Skepticism In The News: Helping Journalists Get It Right

Try to keep out some of the more hysterical claims. --Nbauman (talk) 01:56, 23 November 2009 (UTC)[reply]

FDA approved yesterday

An FDA news release announces:

FDA approves Lynparza to treat advanced ovarian cancer
First LDT companion diagnostic test also approved to identify appropriate patients

Hope this is useful. --Hordaland (talk) 02:08, 20 December 2014 (UTC)[reply]

How many people have taken this?

It would be helpful to get some statistical estimates of how many people have taken this medication. That would help me, as a consumer, evaluate its effectiveness and safety. I think it's a fairly rare medication, but I'm not sure. — Preceding unsigned comment added by Skysong263 (talk • contribs) 15:16, 8 May 2018 (UTC)[reply]

Dangling References

Reference #6 (to: http://www.emea.europa.eu/pdfs/human/comp/opinion/51078707en.pdf ) referes to non-existent target.